ClinicalTrials.gg
Not yet recruitingNCT07947940Updated Nov 19, 2026

Assessing Prognostic Value of Markers of Cardiac Disease Progression in ATTR-CM Patients Treated With Tafamidis

An observational study in ATTR-CM (Transthyretin Amyloid Cardiomyopathy), sponsored by Pfizer. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Pfizer · Observational

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to assess the prognostic utility of various markers of disease progression among patients diagnosed with ATTR-CM treated with tafamidis utilizing Truveta database in the US. We will evaluate the impact of markers of disease progression (such as eGFR, ODI, NT-proBNP, NYHA and KCCQ) at Month 12 after initiation of tafamidis on clinical outcomes (including all-cause mortality, CV-related mortality, first CV hospitalization) among ATTR-CM patients treated with tafamidis in the US.

02

Conditions studied

  • ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include patients with a documented dispensed fill of tafamidis within the Truveta database in the US from January 1, 2020 to the latest data available.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

  1. Patients with at least 1 inpatient or 2 outpatient diagnoses (30 days apart) with ICD-10-CM code for ATTRwt-CM (E85.82), ATTRv-CM (E85.0, E85.2), or organ-limited amyloidosis (E85.4) and with ≥ 1 dispensed fill of tafamidis; OR For those who do not meet the ATTR-CM diagnosis criterion, patients with ≥ 1 dispensed fill of tafamidis;
  2. Age ≥ 18 years on the index date;
  3. With ≥ 6 months' activity before the index date.

Exclusion criteria

Exclusion Criteria

Patients meeting any of the following criteria will not be included in the study:

  1. ≥1 ICD-10-CM diagnosis code for light chain amyloidosis (E85.81) during the study period;
  2. ≥ 1 ICD-10-CM diagnosis code for ATTR-PN (E85.1) or prescription fill for patisiran or eplontersen during the study period;
  3. ≥1 ICD-10-CM for liver or heart transplant during the baseline period (ICD codes included in the SAP);
  4. ≥1 ICD-10-CM code for multiple myeloma during the baseline period (ICD codes included in the SAP);
  5. Dispensed fill for any of the following DMTs during baseline period: tafamidis, acoramidis, vutrisiran (codes included in the SAP);
  6. Dispensed fill for any of the following therapies during the study period (for excluding patients with amyloid light-chain amyloidosis): melphalan, cyclophosphamide, bortezomib, lenalidomide, thalidomide, bendamustine, pomalidomide, carfilzomib, ixazomib, daratumumab, venetoclax, elotuzumab, ibrutinib, rituximab and obinutuzumab (codes included in the SAP).
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1 participant (estimated)

Groups and cohorts

  • ATTR-CM patients treated with tafamidis

    ATTR-CM patients treated with tafamidis

    Drug: Tafamidis

Interventions

  • DrugTafamidis

    As provided in real-world routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Time to All cause Mortality

    Time frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019- June 30, 2026)

  2. Time to Cardiovascular Mortality (CV)

    Time frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019- June 30, 2026)

  3. Time to First (Cardiovascular, Non-Cardiovascular) Hospitalization

    Time frame: From Month 12 after tafamidis initiation through end of follow-up (up to 60+ months) (between July 1, 2019-June 30, 2026)

Secondary outcomes

  1. Change from Baseline in N-terminal pro-B-type natriuretic peptide (NT-proBNP)

    Time frame: Baseline, at diagnosis of ATTR-CM, at treatment initiation, and at Months (12,24,30,36,60)

  2. Change from Baseline in Estimated glomerular filtration rate (eGFR)

    Time frame: Baseline, at diagnosis of ATTR-CM, at treatment initiation, and at Months (12,24,30,36,60)

  3. Change from Baseline in New York Heart Association classification (NYHA)

    Time frame: Baseline, at diagnosis of ATTR-CM, at treatment initiation, and at Months (12,24,30,36,60)

  4. Change from Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Time frame: Baseline, at diagnosis of ATTR-CM, at treatment initiation, and at Months (12,24,30,36,60)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Nov 24, 2026
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947940
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 24, 2026 (estimated)
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Pfizer CT.gov Call Center
Contact
ClinicalTrials.gov_Inquiries@pfizer.com
1-800-718-1021
Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion